Kymera moves up KT-621 atopic dermatitis data after fast enrollment
Faster-than-planned enrollment in the STAT6 degrader's Phase 2b trial pulls the readout forward to year-end 2026 and sets up an earlier Phase 3 start.
Kymera Therapeutics said on August 5, 2026 that it completed enrollment in the KT-621 BROADEN2 Phase 2b trial in moderate to severe atopic dermatitis patients about six months earlier than originally planned1. As a result, the company moved up its topline data readout by six months to year-end 2026, ahead of prior guidance for a mid-2027 readout1. Kymera now expects to start Phase 3 trials in atopic dermatitis by mid-2027, pending discussions with regulators1.
The company's second Phase 2b study of KT-621, in moderate to severe eosinophilic asthma, is still enrolling, and Kymera expects to report data from that trial in late 20271.
In the IRF5 program, Kymera is still enrolling healthy volunteers in a Phase 1 trial of KT-579, with data expected in the fourth quarter of 2026, and plans to start a Phase 1b proof-of-concept trial in lupus patients soon after that trial finishes1.
Among partnered programs, Sanofi started a first-in-human Phase 1 trial of KT-485 (SAR447971), an oral IRAK4 degrader, in healthy volunteers and hidradenitis suppurativa patients in June 20261, triggering a $20 million milestone payment to Kymera1. Separately, Gilead Sciences exercised its option in April 2026 to license KT-200, a CDK2 degrader candidate, triggering a $45 million payment to Kymera1, and Gilead intends to move the program into IND-enabling studies ahead of a planned 2027 IND filing1.
On the balance sheet, Kymera reported $1.5 billion in cash, cash equivalents and investments as of June 30, 2026, which it says provides runway into 20291.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.